-

11:54:25 PM

ZSAN Stock News

ZSAN - Zosano Pharma Corp

05/13/22 4:00 PM

Nasdaq : ZSAN

earningslow float

Zosano Pharma Reports First Quarter 2022 Financial Results

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2022. All share and per share information included in these financial results and

RHEA-AI

negative

04/29/22 4:00 PM

Nasdaq : ZSAN

low float

Zosano Pharma Provides Corporate Update

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today provided a corporate update. On April 14, 2022, the Food and Drug Administration granted Zosano a twelve-month extension to April 20, 2023 to resubmit its

RHEA-AI

neutral

04/11/22 8:00 AM

Nasdaq : ZSAN

low float

Zosano Pharma Announces Reverse Stock Split Effective Today

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its Board of Directors has approved a 1-for-35

RHEA-AI

neutral

03/17/22 4:05 PM

Nasdaq : ZSAN

earningslow float

Zosano Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and year ended December 31, 2021, as well as business updates. “We are in discussions with the FDA to

RHEA-AI

neutral

02/08/22 9:55 PM

Nasdaq : ZSAN

offeringlow float

Zosano Pharma Announces Pricing of $15.4 Million Public Offering of Common Stock and Warrants

Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 51,250,000 units, each consisting of one share of common stock and one

RHEA-AI

neutral

02/08/22 4:10 PM

Nasdaq : ZSAN

offeringlow float

Zosano Pharma Announces Proposed Public Offering of Common Stock and Warrants

Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced that it is commencing an underwritten public offering of units consisting of shares of common stock and warrants to purchase common stock. All of

RHEA-AI

neutral

01/05/22 12:01 PM

Nasdaq : ZSAN

clinical triallow float

CORRECTION - Zosano Pharma Announces Publication of Clinical Data Demonstrating Comparable Immunogenicity of a Trivalent Influenza Vaccine Formulated on its Transdermal Microneedle System Versus an Intramuscular Injection of the Vaccine at a Higher Dose

In a press release published under the same headline today by Zosano Pharma Corporation (Nasdaq:ZSAN), a measurement was incorrectly stated as grams, not micrograms. The measurements of

RHEA-AI

neutral

01/05/22 9:20 AM

Nasdaq : ZSAN

clinical triallow float

Zosano Pharma Announces Publication of Clinical Data Demonstrating Comparable Immunogenicity of a Trivalent Influenza Vaccine Formulated on its Transdermal Microneedle System Versus an Intramuscular Injection of the Vaccine at a Higher Dose

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the publication of Phase 1 clinical trial data in an article titled, “ Immunogenicity

RHEA-AI

neutral

12/13/21 4:30 PM

Nasdaq : ZSAN

managementlow float

Zosano Pharma Announces Changes to Board of Directors; Appoints Cross Functional Business Executive Elaine M. Yang

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced changes to its board of directors, including the appointment of Elaine M. Yang. “We are pleased to welcome Elaine, a high caliber executive, to

RHEA-AI

neutral

11/29/21 9:45 PM

Nasdaq : ZSAN

low float

Zosano Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the Board of Directors granted a stock option to purchase 220,000 shares of Zosano’s common stock to a new employee as an inducement award.

RHEA-AI

neutral

ZSAN Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.zosanopharma.com
CeoSteven Lo
Security nameZosano Pharma Corp
Issue typecs
SectorManufacturing
Sic code2834
Employees45
Tags
- Health Technology
- Medical Specialties
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address34790 Ardentech Ct
StateCalifornia
CityFremont
Zip94555-3657
CountryUS
Phone15107451200

About Zosano Pharma Corp

Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing products where rapid administration of approved molecules with established safety and efficacy profiles may provide substantial benefit to patients, in markets where patients remain underserved by existing therapies. The company's transdermal microneedle system technology consists of titanium microneedles coated with drug that are designed to enable rapid systemic administration of therapeutics to patients. Zosano's lead product candidate is Qtrypta™ (M207), which is a proprietary formulation of zolmitriptan designed to be delivered via its transdermal microneedle system technology, as an acute treatment for migraine.